LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
Between March 13 and March 27, 2019, a series of reports alleged that the Company’s revenue base relied on “an exceedingly generous, but increasingly fragile, reimbursement regime.” These reports also alleged that the Company engaged in deceptive accounting practices.
On this news, iRhythm’s stock price fell $14.02 per share, or over 16%, over several trading sessions to close at $73.24 on March 28, 2019, thereby injuring investors.
Then, on November 13, 2019, iRhythm disclosed that it could not timely file its quarterly report, citing accounting errors affecting prior periods that require further analysis. The Company stated that “[t]hese errors may result in the correction of previously issued annual and quarterly financial statements” and “the error evaluation will include the assessment of any additional control deficiencies.”
On this news, iRhythm’s stock price fell $4.38, or over 6% to close at $63.04 on November 13, 2019, thereby injuring investors further.
If you purchased iRhythm securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.